MUPIROCIN- mupirocin ointment 
Taro Pharmaceuticals U.S.A., Inc.

----------

Mupirocin
Ointment USP, 2%

For dermatologic use on dogs

CAUTION

Federal law restricts this drug to use by or on the order of a licensed veterinarian.

DESCRIPTION

Each gram of mupirocin ointment contains 20 mg of mupirocin in a bland, water-washable ointment base consisting of polyethylene glycol 400 and polyethylene glycol 3350 (polyethylene glycol ointment). Mupirocin is a naturally-occurring, broad-spectrum antibiotic. The chemical name is 9-4-[5S-(2S,3S-epoxy-5S-hydroxy-4S-methylhexyl)-3R,4R-dihydroxytetrahydropyran-2S-yl]-3-methylbut-2(E)-enoyloxy-nonanoic acid. The chemical structure is:

Chemical Structure

CLINICAL PHARMACOLOGY

Mupirocin is a chemical entity produced by fermentation of the organism Pseudomonas fluorescens. Mupirocin inhibits bacterial protein synthesis by reversibly and specifically binding to bacterial isoleucyl transfer-RNA synthetase. Due to this mode of action, mupirocin shows no cross resistance with chloramphenicol, erythromycin, gentamicin, lincomycin, neomycin, novobiocin, penicillin, streptomycin, and tetracycline. Mupirocin is an antimicrobial agent that inhibits the growth of gram-positive and gram-negative bacteria.

Bacteria susceptible to the action of mupirocin in vitro include the aerobic isolates of Staphylococcus aureus (including methicillin-resistant strains and β-lactamase-producing strains), Staphylococcus intermedius, Staphylococcus epidermidis, other coagulase positive or negative Staphylococci, α-hemolytic Streptococci, β group A Streptococci (including S. pyogenes), other β Streptococci (including S. agalactiae), group D Streptococci (including S. faecalis and S. faecium), group Viridans Streptococci, Streptococcus pneumoniae, Corynebacterium hofmanii, Bacillus subtilis, Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, Proteus vulgaris, Enterobacter cloacae, Enterobacter aerogenes, Citrobacter freundii, Hemophilus influenzae (including β-lactamase-producing strains), Neisseria gonorrheae (including β-lactamase-producing strains), Neisseria meningitidis, Branhamella catarrhalis and Pasteurella multocida, and the anaerobic isolates of Peptostreptococcus anaerobius, Clostridium difficile, and Clostridium sporogenes.

Clinical significance of the in vitro data is unknown except for susceptible strains of Staphylcoccus aureus and Staphylococcus intermedius.

INDICATIONS FOR USE

Mupirocin ointment is indicated for the topical treatment of canine bacterial infections of the skin, including superficial pyoderma, caused by susceptible strains of Staphylococcus aureus and Staphylococcus intermedius.

CONTRAINDICATIONS

This drug is contraindicated in animals with a history of sensitivity reactions to any of its components.

WARNINGS

Because of the potential hazard of nephrotoxicity due to the polyethylene glycol content of the base, care should be exercised when using this product in treating extensive deep lesions where absorption of large quantities of polyethylene glycol is possible.

Safety of use in pregnant or breeding animals has not been determined.

Mupirocin ointment is not for ophthalmic use.

ADVERSE REACTIONS

No adverse reactions have been reported with this product. If a skin reaction such as irritation should occur, treatment should be discontinued and appropriate therapy instituted.

DOSAGE AND ADMINISTRATION

Prior to treatment, the lesion should be cleansed. Mupirocin ointment should be applied to the affected area twice a day. Apply a sufficient amount of ointment to completely cover the infected area. Maximum duration of treatment should not exceed 30 days.

HOW SUPPLIED

Mupirocin ointment is supplied in 5 g, 15 g, 22 g, and 30 g tubes.

Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature]

Keep Out of Reach of Children

Approved by FDA under ANADA # 200-457

Mfd. by: Taro Pharmaceuticals Inc. Brampton, Ontario, Canada L6T 1C1

Dist. by: Taro Pharmaceuticals U.S.A., Inc. Hawthorne, NY 10532

Revised: January 2020

PK-6725-2

TAKE TIME

PRINCIPAL DISPLAY PANEL - 22 g Tube Carton

NDC 51672-1354-0

Mupirocin
Ointment USP, 2%

For dermatologic use on dogs.
Caution: Federal law restricts this drug to use by or on the order of a licensed veterinarian.
Approved by FDA under ANADA # 200-457

Net Weight
22 g

Keep Out of Reach of Children.

TARO

PRINCIPAL DISPLAY PANEL - 22 g Tube Carton
MUPIROCIN 
mupirocin ointment
Product Information
Product TypePRESCRIPTION ANIMAL DRUGItem Code (Source)NDC:51672-1354
Route of AdministrationTOPICAL
Active Ingredient/Active Moiety
Ingredient NameBasis of StrengthStrength
Mupirocin (UNII: D0GX863OA5) (Mupirocin - UNII:D0GX863OA5) Mupirocin20 mg  in 1 g
Inactive Ingredients
Ingredient NameStrength
polyethylene glycol 400 (UNII: B697894SGQ)  
polyethylene glycol 3350 (UNII: G2M7P15E5P)  
Product Characteristics
ColorWHITE (cream-like) Score    
ShapeSize
FlavorImprint Code
Contains    
Packaging
#Item CodePackage DescriptionMarketing Start DateMarketing End Date
1NDC:51672-1354-51 in 1 CARTON
15 g in 1 TUBE
2NDC:51672-1354-11 in 1 CARTON
215 g in 1 TUBE
3NDC:51672-1354-01 in 1 CARTON
322 g in 1 TUBE
4NDC:51672-1354-21 in 1 CARTON
430 g in 1 TUBE
Marketing Information
Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
ANADAANADA20045711/29/2010
Labeler - Taro Pharmaceuticals U.S.A., Inc. (145186370)
Establishment
NameAddressID/FEIBusiness Operations
Taro Pharmaceuticals Inc.206263295MANUFACTURE
Establishment
NameAddressID/FEIBusiness Operations
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd654019884API MANUFACTURE
Establishment
NameAddressID/FEIBusiness Operations
Teva Pharmaceutical Works Private Limited Company366709764API MANUFACTURE

Revised: 6/2020
Document Id: bc36adbc-1ac5-4803-97cf-1e6c7675fd69
Set id: 86248181-cdd7-4eaf-8b1a-ef5c1b301d06
Version: 3
Effective Time: 20200625
 
Taro Pharmaceuticals U.S.A., Inc.